Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opicapone 50 mg pilot study in Parkinson's disease with end-of-dose motor fluctuations and sleep disorders
2020-001176-15Phase 4Completed
- Sponsor
- BIAL
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of opicapone in Parkinson's disease (PD), sponsored by BIAL. Primary endpoint: Total score of Parkinson's Disease Sleep Scale version 2. Started Dec 2020; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2020-001176-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001176-15.